Abstract
Scientists have tried for many years to understand cancer development and progression in the expectation of defining the therapeutic target. Emerging evidence has revealed that cancers contain a minority population, termed “Cancer stem cells (CSCs)”, which are responsible for sustaining the tumour as well as giving rise to proliferating cells. CSCs are thought share the three features with normal stem cells: self-renewal, the capability give rise to multiple lineages, the potential to proliferate extensively and therefore it has been proposed that they have their origin in normal stem cells. However, since there is evidence that genetic alterations occurring in committed progenitor cells can reactive their proliferative potential, the origin of CSCs still remains undecided. In this review, we discuss the current status of cancer stem cells in various tissues, the origin of some cancers from normal stem cells, the evidence for the existence of particular markers and aspects of their cell biology. Better understanding of the relation between adult stem cells and cancer stem cells in tumourigenesis may will provide novel therapeutic strategies against cancers.
Keywords: Stem cells, cancer stem cells, side population (SP), non-SP, tumourigenesis, mitochondria
Current Cancer Therapy Reviews
Title: Cancer and Stem Cells
Volume: 4 Issue: 3
Author(s): Lydia Gutierrez-Gonzalez, Osamu Inatomi, Julia Burkert and Nichoals A. Wright
Affiliation:
Keywords: Stem cells, cancer stem cells, side population (SP), non-SP, tumourigenesis, mitochondria
Abstract: Scientists have tried for many years to understand cancer development and progression in the expectation of defining the therapeutic target. Emerging evidence has revealed that cancers contain a minority population, termed “Cancer stem cells (CSCs)”, which are responsible for sustaining the tumour as well as giving rise to proliferating cells. CSCs are thought share the three features with normal stem cells: self-renewal, the capability give rise to multiple lineages, the potential to proliferate extensively and therefore it has been proposed that they have their origin in normal stem cells. However, since there is evidence that genetic alterations occurring in committed progenitor cells can reactive their proliferative potential, the origin of CSCs still remains undecided. In this review, we discuss the current status of cancer stem cells in various tissues, the origin of some cancers from normal stem cells, the evidence for the existence of particular markers and aspects of their cell biology. Better understanding of the relation between adult stem cells and cancer stem cells in tumourigenesis may will provide novel therapeutic strategies against cancers.
Export Options
About this article
Cite this article as:
Gutierrez-Gonzalez Lydia, Inatomi Osamu, Burkert Julia and Wright A. Nichoals, Cancer and Stem Cells, Current Cancer Therapy Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339408785294249
DOI https://dx.doi.org/10.2174/157339408785294249 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Homologation: A Versatile Molecular Modification Strategy to Drug Discovery
Current Topics in Medicinal Chemistry Tumor Biomarkers: Clinical Utility, Promises and Problems
Applied Clinical Research, Clinical Trials and Regulatory Affairs Editorial (Thematic Issue: Antiangiogenic Agents in the Management of Solid Malignancies)
Current Angiogenesis (Discontinued) Plumbagin Inhibits Breast Tumor Bone Metastasis and Osteolysis by Modulating the Tumor-Bone Microenvironment
Current Molecular Medicine Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Role of ABC Transporters in Veterinary Drug Research and Parasite Resistance
Current Drug Delivery The Synthesis of Nano-Doxorubicin and its Anticancer Effect
Anti-Cancer Agents in Medicinal Chemistry The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets Glycoconjugates As Vaccines for Cancer Immunotherapy: Clinical Trials and Future Directions
Anti-Cancer Agents in Medicinal Chemistry Garlic-Derived Allyl Sulfides in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Anti-Inflammatory Actions of the Heme Oxygenase-1 Pathway
Current Pharmaceutical Design Chemoinformatics Approaches for Traditional Chinese Medicine Research and Case Application in Anticancer Drug Discovery
Current Drug Discovery Technologies In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology 3,6-dichloro-1,2,4,5-Tetrazine Assayed at High Doses in the Metastatic Breast Cancer Cell Line MDA-MB-231 Reduces Cell Numbers and Induces Apoptosis
Current Bioactive Compounds Current and Potential Chemotherapeutic Agents Used for Induction Chemotherapy in the Treatment of Breast Cancer
Current Pharmaceutical Design Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Network Effect of Wt-mutant p53 Interactions and Implications on p53 Gene Therapy
Current Pharmaceutical Design Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization
Anti-Cancer Agents in Medicinal Chemistry Retraction Notice: The Benefits and Risks of Different Therapies in Preventing Postoperative Nausea and Vomiting in Patients Undergoing Thyroid Surgery
Current Drug Safety Cyclometalated Complexes of Platinum and Gold with Biological Properties: State-of-the-Art and Future Perspectives
Current Medicinal Chemistry